Curis Inc (CRIS)

[Desert dweller]

Operable BCC results due any day now. From the 3rd qtr 10q

Tried posting over on Yahoo but that site isn't working and I think from now on I will begin posting here instead. Hopefully the regulars on Yahoo come over here. I have always liked this site better anyway but there haven't been enough people posting related to Curis here but hopefully that will change.

Here is a potential catalyst that could come out any day now. According to the 3rd qtr 10q, data from the operable bcc study could come out by end of year or early 2012.

Genentech is also conducting a separate phase II clinical trial of vismodegib in patients with operable nodular basal cell carcinoma, which is a less severe form of the disease and accounts for a significant percentage of the approximately two million BCCs diagnosed annually in the United States. This study was initiated by Genentech in October 2010 to test vismodegib as a single-agent therapy in approximately 50 patients with operable nodular BCC in a US-based, open label, two-cohort clinical trial. All patients will receive a 150 mg daily oral dose of vismodegib for 12 weeks. The primary outcome measure for the first cohort is the rate of complete histological clearance of target nodular BCC lesions at the time of tumor excision (which may occur up to 12 weeks following initiation of treatment) while the primary outcome measure for the second cohort is the rate of durable complete clearance of target nodular BCC lesions at the time of excision (which may occur up to 36 weeks following initiation of treatment). We expect that data will be available from this trial later this year or early in 2012. We also anticipate that Genentech will provide us with its plans for future development in operable BCC within this timeframe and we look forward to providing further updates on this in the future.